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This data article presents a dataset of total, oligomeric alpha-
synuclein and hemoglobin levels in plasma of drug-naïve PD
patients and controls. This is the ﬁrst attempt to assess the effect of
hemolysis rate on oligomeric alpha-synuclein levels in peripheral
plasma. The data are associated with the research article “Oligo-
meric alpha-synuclein and glucocerebrosidase activity levels in
GBA-associated Parkinson's disease” (Pchelina et al., 2016) [1].
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Value of the data
 These data provide the correlation between oligomeric alpha-synuclein and hemoglobin plasma
levels in drug-naive PD patients and controls.
 The data are of value for further experiments on the assessing of alpha-synuclein levels in
peripheral blood and cerebrospinal ﬂuid (CSF) samples.
 The data have signiﬁcance due to the fact that hemolysis has effect on total but not oligomeric
alpha-synuclein levels in peripheral blood plasma.1. Data
Signiﬁcant positive correlation of total alpha-synuclein with hemoglobin levels was observed in
combined group of iPD patients and controls (r¼0,714; po0,0001) and separately (for iPD patients –
r¼0,656; p¼0,004; for controls – r¼0,746; po0,0001) (Fig. 1). However, the correlation between
oligomeric alpha-synuclein and hemoglobin levels in the above mentioned groups was absent (for
combined group – r¼0,198; p¼0,254; for iPD – r¼0,234; p¼0,366; for controls – r¼0,049;
p¼0,848). We did not ﬁnd any signiﬁcant difference in total, oligomeric alpha-synuclein levels and
oligomeric/total alpha-synuclein ratio between iPD patients and controls (Table 1) [1].alpha-synuclein species and hemoglobin plasma levels in combined group of PD patients and
tion between total alpha-synuclein and hemoglobin levels (r¼0,714; po0,0001). (B) Correlation
nuclein and hemoglobin levels (r¼0, 198; p¼0,254).
Table 1
Alpha-synuclein (total, oligomeric) levels in iPD patients and controls.
iPD patients Controls p
Total alpha-synuclein, (median
(min–max)), ng/ml
3.89 (0.15–
51.11)
3.88 (1.26–
23.24)
0.478
Oligomeric alpha-synuclein, (median
(min–max)), pg/ml
4.14 (0.73–
40.9)
5.42 (1.05–
129.19)
0.766
Oligomeric/total alpha-synuclein
(median (min–max)), %
0.15 (0.006–
2.033)
0.13 (0.01–
6.63)
0.692
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2.1. Sample preparation
Blood plasma samples were collected from 17 drug-naïve patients with iPD (mean age
62.4479.67, 6 males) and age/sex-matched 18 controls (mean age 63.83710.86, 10 males). PD
patients were diagnosed with PD at Pavlov First Saint Petersburg State Medical University, Saint-
Petersburg, Russia. Subjects without neurological disorders were included in the control group. The
study was approved by the local ethics committee. All the participating subjects provided informed
consent. Samples were collected using centrifugation at 3000 rpm at 4 °C for 20 min. All samples
were aliquoted and maintained at 70 °C.
2.2. ELISA assays to measure total, oligomeric alpha-synuclein and hemoglobin levels
Total alpha-synuclein, oligomeric alpha-synuclein and hemoglobin levels were estimated by
means of enzyme-linked immunosorbent assay (ELISA) (Human alpha-synuclein ELISA kit (Invitro-
gen, USA), Human Synuclein OLIGO kit (ajRoboscreen, Germany) and Hemoglobin (Human) ELISA kit
(Abnova, USA), accordingly), as described previously [2–4]. Levels of oligomeric alpha-synuclein were
estimated by means of ELISA with 5G4 antibodies designated for detection of alpha-synuclein oli-
gomers in human ﬂuid samples [5]. Undiluted plasma samples were examined in case of alpha-
synuclein measurements. For hemoglobin level estimation plasma samples were diluted according
the manufacturer's recommendations. In all ELISA assays each sample was measured in triplicate.
2.3. Statistical analysis
To assess differences between groups, the Mann–Whitney test was used, and the correlations were
evaluated by exponential regression analysis. The correlations were evaluated using the Spearman
correlation coefﬁcient. Sex variables were analyzed by Chi-square and Fisher's exact tests. Experi-
mental data are given as median (min–max). The level of signiﬁcance was set at po0.05. Statistical
analysis was carried out using SPSS 12.0.Acknowledgment
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